Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

Abstract

In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19 + acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which can lead to rapid cardiorespiratory and/or neurological deterioration. Multidisciplinary medical vigilance and the requisite health-care infrastructure are imperative to ensuring optimal patient outcomes, especially as these therapies transition from research protocols to standard care. Herein, authors representing the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Stem Cell Transplantation (HSCT) Subgroup and the MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program have collaborated to provide comprehensive consensus guidelines on the care of children receiving CAR T cell therapy.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 147

1. 1.

   Noone, A. M. et al. SEER Cancer Statistics Review, 1975–2015. National Cancer Institutehttps://seer.cancer.gov/csr/1975_2015/ (2018).

   Not in our library

2. 2.

   Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N. Engl. J. Med. 1948;238:787-793.

   Not in our library10.1056/nejm194806032382301

3. 3.

   O’Leary M, Krailo M, Anderson JR, Reaman GH, Children’s Oncology Group. Progress in childhood cancer: 50 years of research collaboration, a report from the Children’s Oncology Group. Semin. Oncol. 2008;35:484-493.

   Not in our library10.1053/j.seminoncol.2008.07.008

4. 4.

   Blau, C. A. E. Donnall Thomas, M.D. (1920–2012). Stem Cells Transl Med. (2013).

   Not in our library

5. 5.

   Ko RH, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J. Clin. Oncol. 2010;28:648-654.

   Not in our library10.1200/jco.2009.22.2950

6. 6.

   Sun, W. et al. Outcome of children with multiply relapsed B cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia and lymphoma study. Leukemia10.1038/s41375-018-0094-0 (2018).

   Not in our library10.1038/s41375-018-0094-0

7. 7.

   Thomas ED, et al. Marrow transplantation for patients with acute lymphoblastic leukemia in remission. Blood. 1979;54:468-476.

   Not in our library

8. 8.

   Novartis Pharmaceuticals Corporation. Package insert - KymriahTM (tisagenlecleucel). Novartis Pharmaceuticals Corporationhttps://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM573941.pdf (2018).

   Not in our library

9. 9.

   Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 2014;371:1507-1517.

   Not in our library10.1056/nejmoa1407222

10. 10.

    Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-cells for cancer therapy. J. Natl Cancer Inst. 2016;108:djv439.

    Not in our library10.1093/jnci/djv439

11. 11.

    Kebriaei P, et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J. Clin. Invest. 2016;126:3363-3376.

    Not in our library10.1172/jci86721

12. 12.
    CAR models: next-generation CAR modifications for enhanced T-cell function · 2016

    Not checked
13. 13.

    Maus MV, Levine BL. Chimeric antigen receptor T-cell therapy for the community oncologist. Oncologist. 2016;21:608-617.

    Not in our library10.1634/theoncologist.2015-0421

14. 14.

    Kochenderfer JN, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116:4099-4102.

    Not in our library10.1182/blood-2010-04-281931

15. 15.

    Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011;365:725-733.

    Not in our library10.1056/nejmoa1103849

16. 16.

    Grupp SA, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013;368:1509-1518.

    Not in our library10.1056/nejmoa1215134

17. 17.

    Brentjens RJ, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl Med. 2013;5:177ra138.

    Not in our library10.1126/scitranslmed.3005930

18. 18.

    Cruz CR, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122:2965-2973.

    Not in our library10.1182/blood-2013-06-506741

19. 19.

    Kochenderfer JN, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:4129-4139.

    Not in our library10.1182/blood-2013-08-519413

20. 20.

    Davila ML, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl Med. 2014;6:224ra225.

    Not in our library10.1126/scitranslmed.3008226

21. 21.

    Kochenderfer JN, et al. Chemotherapy-refractory diffuse large B cell lymphoma and indolent B cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 2015;33:540-549.

    Not in our library10.1200/jco.2014.56.2025

22. 22.

    Lee DW, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517-528.

    Not in our library10.1016/s0140-6736(14)61403-3

23. 23.

    Garfall AL, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N. Engl. J. Med. 2015;373:1040-1047.

    Not in our library10.1056/nejmoa1504542

24. 24.

    Brudno JN, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 2016;34:1112-1121.

    Not in our library10.1200/jco.2015.64.5929

25. 25.

    Turtle CJ, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J. Clin. Oncol. 2017;35:3010-3020.

    Not in our library10.1200/jco.2017.72.8519

26. 26.

    Locke FL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol. Ther. 2017;25:285-295.

    Not in our library10.1016/j.ymthe.2016.10.020

27. 27.

    Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 2017;377:2531-2544.

    Not in our library10.1056/nejmoa1707447

28. 28.

    Kochenderfer JN, et al. B cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709-2720.

    Not in our library10.1182/blood-2011-10-384388

29. 29.

    Lee DW, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188-195.

    Not in our library10.1182/blood-2014-05-552729

30. 30.

    Teachey DT, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121:5154-5157.

    Not in our library10.1182/blood-2013-02-485623

31. 31.
    The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer · 2015

    No notice
32. 32.

    Richman SA, et al. High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer. Immunol. Res. 2018;6:36-46.

    Not in our library10.1158/2326-6066.cir-17-0211

33. 33.

    Fitzgerald JC, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit. Care Med. 2017;45:e124-e131.

    Not in our library10.1097/ccm.0000000000002053

34. 34.

    Norelli M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 2018;24:739-748.

    Not in our library10.1038/s41591-018-0036-4

35. 35.

    Giavridis T, et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 2018;24:731-738.

    Not in our library10.1038/s41591-018-0041-7

36. 36.

    FDA. FDA briefing document: Oncologic Drugs Advisory Committee meeting; BLA 125646; Tisagenlecleucel, Novartis Pharmaceuticals Corporation. FDAhttps://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM566166.pdf (2017).

    Not in our library

37. 37.

    Neelapu SS, et al. Chimeric antigen receptor T cell therapy - assessment and management of toxicities. Nat. Rev. Clin. Oncol. 2018;15:47-62.

    Not in our library10.1038/nrclinonc.2017.148

38. 38.

    Maude SL, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 2018;378:439-448.

    Not in our library10.1056/nejmoa1709866

39. 39.

    Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am. J. Publ. Health. 1984;74:979-983.

    Not in our library10.2105/ajph.74.9.979

40. 40.

    Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Developing clinical guidelines. West J. Med. 1999;170:348-351.

    Not in our library

Cited by papers we hold 4

• Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies · 2021
  No notice
• The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma · 2020
  No notice
• Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies · 2020
  No notice
• CAR T Cell Toxicity: Current Management and Future Directions · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.